文献速递肝病

HDL相关生物标志物是慢性肝衰竭患者生存的稳健预测指标

HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure.
PubMed 文献 · J Hepatol · 2020-02-14

该研究在508例代偿或失代偿期肝硬化患者(含慢加急性肝衰竭)及40名年龄性别匹配对照中,检测HDL-C、HDL2-C、HDL3-C、载脂蛋白A1及HDL胆固醇流出能力。结果显示HDL-C和apoA-I是独立于MELD评分的预测指标,对90天死亡率诊断准确性高,并在985例门脉高压患者外部验证队列中验证了HDL-C的预后准确性。

要点

  • HDL-C和apoA-I在稳定期肝硬化中可独立于MELD评分预测肝脏相关并发症。
  • 在失代偿期肝硬化(含ACLF)中,HDL-C和apoA-I是90天死亡的MELD独立预测因子。
  • HDL-C<17 mg/dl和apoA-I<50 mg/dl提示短期生存差。

核心结论

  • HDL相关生物标志物是慢性肝衰竭疾病进展和生存的稳健预测指标。

研究设计与样本

  • 研究纳入508例代偿或失代偿期肝硬化患者(含ACLF)及40名年龄和性别匹配对照,检测HDL相关生物标志物。
  • 预后准确性在985例晚期慢性肝病所致门脉高压患者的外部验证队列中验证。

主要发现

  • 稳定期肝硬化患者基线HDL-C和apoA-I水平显著低于对照,在急性失代偿和ACLF患者中进一步降低。
  • 在稳定期肝硬化(n=228)中,HDL-C和apoA-I独立于MELD评分预测肝脏相关并发症的发生。
  • 在急性失代偿患者(伴或不伴ACLF,n=280)中,HDL-C和apoA-I是90天死亡的MELD独立预测因子。
  • ROC分析显示,HDL-C和apoA-I对急性失代偿患者90天死亡的AUROC分别为0.79和0.80,与MELD的0.81相似。
  • 外部验证队列中HDL-C的AUROC为0.81,MELD为0.77。

关键数值与推荐

  • HDL-C<17 mg/dl和apoA-I<50 mg/dl提示短期生存差。
  • 急性失代偿患者90天死亡AUROC:HDL-C 0.79,apoA-I 0.80,MELD 0.81。
  • 外部验证队列AUROC:HDL-C 0.81,MELD 0.77。

临床怎么用

  • HDL-C和apoA-I可在临床实验室常规测量,可作为慢性肝衰竭患者预后评估的简易指标。
  • HDL-C和apoA-I的预后价值与需复杂公式计算的MELD评分相当,可辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: High-density lipoprotein cholesterol (HDL-C) levels are reduced in patients with chronic liver disease and inversely correlate with disease severity. During acute conditions such as sepsis, HDL-C levels decrease rapidly and HDL particles undergo profound changes in their composition and function. We aimed to determine whether indices of HDL quantity and quality associate with progression and survival in patients with advanced liver disease. METHODS: HDL-related biomarkers were studied in 508 patients with compensated or decompensated cirrhosis (including acute-on-chronic liver failure [ACLF]) and 40 age- and gender-matched controls. Specifically, we studied levels of HDL-C, its subclasses HDL2-C and HDL3-C, and apolipoprotein A1 (apoA-I), as well as HDL cholesterol efflux capacity as a metric of HDL functionality. RESULTS: Baseline levels of HDL-C and apoA-I were significantly lower in patients with stable cirrhosis compared to controls and were further decreased in patients with acute decompensation (AD) and ACLF. In stable cirrhosis (n = 228), both HDL-C and apoA-I predicted the development of liver-related complications independently of model for end-stage liver disease (MELD) score. In patients with AD, with or without ACLF (n = 280), both HDL-C and apoA-I were MELD-independent predictors of 90-day mortality. On ROC analysis, both HDL-C and apoA-I had high diagnostic accuracy for 90-day mortality in patients with AD (AUROCs of 0.79 and 0.80, respectively, similar to that of MELD 0.81). On Kaplan-Meier analysis, HDL-C <17 mg/dl and apoA-I <50 mg/dl indicated poor short-term survival. The prognostic accuracy of HDL-C was validated in a large external validation cohort of 985 patients with portal hypertension due to advanced chronic liver disease (AUROCs HDL-C: 0.81 vs. MELD: 0.77). CONCLUSION: HDL-related biomarkers are robust predictors of disease progression and survival in chronic liver failure. LAY SUMMARY: People who suffer from cirrhosis (scarring of the liver) have low levels of cholesterol carried by high-density lipoproteins (HDL-C). These alterations are connected to inflammation, which is a problem in severe liver disease. Herein, we show that reduced levels of HDL-C and apolipoprotein A-I (apoA-I, the main protein carried by HDL) are closely linked to the severity of liver failure, its complications and survival. Both HDL-C and apoA-I can be easily measured in clinical laboratories and are as good as currently used prognostic scores calculated from several laboratory values by complex formulas.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Trieb M, Rainer F, Stadlbauer V, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol. 2020. PMID: 32061870. doi:10.1016/j.jhep.2020.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。